Determining Predictors of Benefit in Psychedelic‑Assisted Mental Health Treatment

Researchers at Charité – Universitätsmedizin Berlin have analyzed therapist experiences worldwide to pinpoint which patients benefit most from psychedelic-assisted therapy, such as psilocybin or LSD treatments for mental health disorders. The study, published in *Nature Mental Health*, reveals that while some patients—like a middle-aged woman with long-term depression—experience profound emotional healing and lasting relief after a single session, others endure worsening symptoms. The first patient, who had failed conventional treatments, described her psilocybin session as a transformative yet painful experience, leading to her first depression remission in over a decade. Psychedelic substances like psilocybin and LSD have shown promise in treating therapy-resistant depression, anxiety, and addiction, with effects potentially linked to increased brain flexibility. However, outcomes vary dramatically. A second patient, similarly diagnosed and situated, described the session as torturous, leaving her more hopeless rather than relieved. Researchers emphasize the need for precise patient selection, comparing psychedelic therapy to using a 'sharp blade'—effective when applied correctly but risky if misused. The study highlights that even one or two guided sessions can produce significant results, but therapists must identify suitable candidates to avoid harm. Factors influencing success remain unclear, though the findings suggest that emotional openness and prior mental resilience may play a role. PD Dr. Felix Betzler, the study’s lead author, stresses the importance of understanding when and how to apply these treatments to maximize benefits while minimizing risks. Charité’s research builds on decades of scientific exploration into psychedelics, which have been studied for over 70 years as potential therapeutic tools. The team’s work aims to refine patient selection criteria, ensuring that only those likely to benefit undergo psychedelic-assisted therapy. This approach could help bridge the gap between promising clinical results and the unpredictable nature of individual responses.